Literature DB >> 32320704

Identification of cofilin-1 as a novel mediator for the metastatic potentials and chemoresistance of the prostate cancer cells.

Liankuai Chen1, Jialong Cai1, Yishan Huang1, Xiangpeng Tan1, Qiuxiao Guo1, Xiaomian Lin1, Cairong Zhu2, Xiangfeng Zeng1, Hongjiao Liu3, Xiaoping Wu4.   

Abstract

Prostate cancer (PCa) is the most common malignancy among men. Tumor metastasis and chemoresistance contribute to the major cause of the mortality. In this study, we compared the protein profiles of two prostate cancer cell lines with different metastatic potentials, and identified cofilin-1 (CFL1) was one of the most differentially expressed proteins between two cell lines. Further results suggested that cofilin-1 promoted the remodeling of F-actin cytoskeleton, and enhanced the proliferation, migration and invasion of the prostate cancer cells via activation of P38 MAPK signaling pathway. In addition, cofilin-1 elevated the expression and drug efflux activity of multidrug resistance protein 1 (MDR1) by P38 MAPK signaling pathway, resulting in decrease of the adriamycin-induced apoptosis as well as the lytic cell death, and the subsequent resistance against adriamycin. Collectively, cofilin-1 might serve as a novel target candidate for both inhibiting the metastasis and reversing the chemoresistance of PCa.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemoresistance; Cofilin-1; Metastasis; Prostate cancer; Proteomics

Year:  2020        PMID: 32320704     DOI: 10.1016/j.ejphar.2020.173100

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  BAIAP2L1 enables cancer cell migration and facilitates phospho-Cofilin asymmetry localization in the border cells.

Authors:  Nut Pipatpanyanugoon; Nicha Wareesawetsuwan; Sunisa Prasopporn; Wannapan Poolex; Trairak Pisitkun; Worasak Kaewkong; Somponnat Sampattavanich; Siwanon Jirawatnotai
Journal:  Cancer Commun (Lond)       Date:  2021-11-23

Review 2.  Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.

Authors:  Milad Ashrafizadeh; Mahshid Deldar Abad Paskeh; Sepideh Mirzaei; Mohammad Hossein Gholami; Ali Zarrabi; Farid Hashemi; Kiavash Hushmandi; Mehrdad Hashemi; Noushin Nabavi; Francesco Crea; Jun Ren; Daniel J Klionsky; Alan Prem Kumar; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.